GlassScriptPhysician profile
William A Hays
NPI 1518900554
$10,070.73
in general payments reported to CMS, 2019-2025
33 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $1,130 · 2021: $1,561 · 2022: $1,174 · 2023: $1,232 · 2024: $1,299 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,045.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,195.60 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $2,094.72 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $1,065.16 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Novo Nordisk INC | $533.83 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Biotech, INC. | $474.73 | 2019-2023 | Prezcobix |
| Theratechnologies INC. | $432.30 | 2019-2025 | Trogarzo, Egrifta |
| Lilly USA, LLC | $324.25 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Emd Serono, INC. | $284.94 | 2020-2025 | Serostim |
| Amarin Pharma, INC. | $259.66 | 2019-2021 | |
| Janssen Products, LP | $248.69 | 2019-2022 | |
| Antares Pharma, INC. | $193.64 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Scientific Affairs, LLC | $143.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $133.98 | 2020-2023 | Farxiga |
| Amgen INC. | $83.43 | 2022-2023 | Repatha |
| Abbvie INC. | $76.29 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $73.85 | 2023 | Aptima |
| Allergan, INC. | $49.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.55 | 2021-2022 | |
| Pfizer INC. | $43.15 | 2025 | |
| Abbott Laboratories | $40.89 | 2021-2024 | Ensite |
| Glaxosmithkline, LLC. | $31.20 | 2019-2021 | |
| Vbi Vaccine (Delaware) INC. | $29.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.57 | 2023 | Spravato |
| Azurity Pharmaceuticals, INC. | $23.76 | 2025 | Azmiro |
| Medtronic, INC. | $22.79 | 2022 | |
| Halozyme INC | $21.84 | 2023 | |
| Arbor Pharmaceuticals, INC. | $19.73 | 2021 | |
| Napo Pharmaceuticals INC | $19.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.29 | 2021 | |
| Genentech USA, INC. | $17.96 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.99 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.63 | 2021 | |
| Dynavax Technologies Corporation | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.